BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application

Reuters

Feb 10

BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application

** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain

** Stock on track for the biggest one-day pct gain since Nov. 11, 2024

** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024

** CanSino said China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years

** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co

** Hong Kong's healthcare index .HSCIH rises 1.4%, Hang Seng Index .HSI surges 1.7%

** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2510883928"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510883928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510883928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510883928","market":"us","top_or_hot":-1,"title":"BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application</title></head><body><p>** Hong Kong shares of vaccine producer CanSino Biologics Inc <span>6185.HK</span> jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain</p><p>** Stock on track for the biggest one-day pct gain since Nov. 11, 2024</p><p>** Shanghai-listed stock <span>688185.SS</span> climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024</p><p>** <span>CanSino said</span> China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years </p><p>** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co</p><p>** Hong Kong's healthcare index <span>.HSCIH</span> rises 1.4%,     Hang Seng Index <span>.HSI</span> surges 1.7%</p><p>** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%  </p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-10 14:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application</title></head><body><p>** Hong Kong shares of vaccine producer CanSino Biologics Inc <span>6185.HK</span> jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain</p><p>** Stock on track for the biggest one-day pct gain since Nov. 11, 2024</p><p>** Shanghai-listed stock <span>688185.SS</span> climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024</p><p>** <span>CanSino said</span> China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years </p><p>** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co</p><p>** Hong Kong's healthcare index <span>.HSCIH</span> rises 1.4%,     Hang Seng Index <span>.HSI</span> surges 1.7%</p><p>** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%  </p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688185","symbol_name":"康希诺","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL1N3P106K:1","article_id":"2510883928","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510883928","pubTimestamp":1739168233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain** Stock on track for the biggest one-day pct gain since Nov. 11, 2024** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024** CanSino said China's National Medical Products Administration  granted priority review status to the firm's new drug application  for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years ** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co** Hong Kong's healthcare index .HSCIH rises 1.4%,     Hang Seng Index .HSI surges 1.7%** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","BK0239":"医药制造","BK1191":"制药","BK1515":"抗疫概念","06185":"康希诺生物","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"BUZZ-康希诺股价上涨，NMPA授予婴儿疫苗申请优先审评资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain** Stock on track for the biggest one-day pct gain since Nov. 11, 2024** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024** CanSino said China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years ** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co** Hong Kong's healthcare index .HSCIH rises 1.4%,     Hang Seng Index .HSI surges 1.7%** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%   (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}